The higher frequency of KRAS mutations was clearly more evident (although not statistically significant) in cancers with a residual serrated adenoma (57.1%, 16/28), being observed twice as often as BRAF mutations (28.6%, 8/28). The gene discussed is BRAF; the disease is cancer.